Bio-Rad Laboratories (US.BIO)
Capital Allocation Audit · Period: 2010 – 2026
Key Metrics
US.BIO · YoY: 2026 Q1 vs 2025 Q1
| Metric | Value | YoY |
|---|---|---|
| FCF Conversion | 72.2% | → |
| ROE | -7.7% | ↓ |
| Cash Conversion | - | → |
| D/E Ratio | 0.20 | → |
| Gross Margin | 52.3% | → |
US.BIO (Bio-Rad Laboratories) | YoY: 2026 Q1 vs 2025 Q1 Metric Value YoY --------------------------- FCF Conversion 72.2% → ROE -7.7% ↓ Cash Conversion - → D/E Ratio 0.20 → Gross Margin 52.3% →
Key Metrics
US.BIO (Bio-Rad Laboratories) | YoY: 2026 Q1 vs 2025 Q1
Metric Value YoY---------------------------FCF Conversion 72.2% →ROE -7.7% ↓Cash Conversion - →D/E Ratio 0.20 →Gross Margin 52.3% →Audit Dimensions
Unlimited Companies
AppleMicrosoftAlphabet-AAmazonNVIDIAMeta PlatformsTeslaBerkshire Hathaway-BJPMorganVisaJohnson & JohnsonWalmartProcter & GambleExxon MobilUnitedHealthHome DepotMasterCardPfizerAbbVieCoca-ColaPepsiCoCostcoNetflixAdvanced Micro DevicesSalesforceDisneyNikeBoeingCaterpillarGoldman SachsAlibabaPDD HoldingsJD.comNIO IncLi AutoBaiduTaiwan SemiconductorASML HoldingEli Lilly and CoBroadcomCiscoOracleIntelAT&TVerizonMerck & CoTexas InstrumentsUnited Parcel ServiceRTX CorpLowe's Companies